Establishment Labs Beats Quarterly Estimates on Strong Revenue Growth
Establishment Labs Holdings Inc. (NASDAQ:ESTA), a medical technology company focused on women's health, announced third-quarter 2025 financial results on November 5, 2025, that surpassed analyst expectations for both earnings and revenue.
The company reported a quarterly loss of $0.38 per share, which was a 29.63% positive surprise compared to the Zacks Consensus Estimate of a $0.54 loss. Revenue for the quarter ending in September 2025 came in at $53.78 million, beating consensus estimates by 3.45%. This represented a significant 33.8% increase from the $40.23 million reported in the same period of the previous year. The revenue growth was partly driven by $11.9 million in sales from its Motiva products.
Following the earnings release, the company's stock price increased by 7.27% to $64.91. This is near its 52-week high of $65.10, with the 52-week low being $26.56. On November 6, 2025, investment firm Needham raised its price target for ESTA to $70, maintaining a Buy rating. The company's market capitalization stands at approximately $1.88 billion.
Establishment Labs is a company centered on breast aesthetics and reconstruction. For more details on the company, see its history and mission and vision. Further information regarding the company's financial standing can be found in its financial health report, and for those interested in investment patterns, see the investor profile.
Establishment Labs Holdings Inc. (ESTA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.